University of Kansas

Other

The United States of America, as Represented by the Secretary, Department of Health and Human Services

The University of North Carolina at Chapel Hill

Myrexis, Inc.

Myriad Pharmaceuticals, Inc.

The General Hospital Corporation

The University of New Mexico

The Broad Institute, Inc.

Myriad Genetics, Inc.

Manfredi, John

Warren S Weiner

Mark B Anderson

Rachel M Slade

Ruth J Walton

Yevgeniya Klimova

Robert J Halter

Ashantai J Yungai

Kenton Zavitz

Jon Adam Willardsen

Noel Terrence Southall

Xin Hu

Kevin Frankowski

Marc Ferrer

David Robert Sibley

Joseph Perry Steiner

Jeffrey Aubé

R Benjamin Free

Amy Elizabeth Moritz

Larry A Sklar

Bruce S Edwards

Jeffrey Aube

Frank John Schoenen

Jennifer Elizabeth Golden

John P Manfredi

David E Fisher

Richard Smith Larson

Christine A Klein

Chad Schroeder

Andrew Gassman

Tuanli Yao

Patrick Faloon

Rizwan Haq

Robert Smith

Kazuyuki Suzuki

Leena Bhoite

Juan Jacob Strouse

Irena Ivnitski-Steele

Hadya M Khawaja

Jerec Warren Ricci

J Adam Willardsen

Matthew Reeder

Yevgeniya I Klimova

The disclosure of a compound of Formula I or a pharmaceutically acceptable salt thereof

Selective D3 dopamine receptor agonists and methods of their use

The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R, R, R, and Rare defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.

Selective Ddopamine receptor agonists and methods of their use

Provided herein are compounds of the formula (IV) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful as MITF inhibitors, MITF pathway inhibitors and for the treatment of cancer. 

Inhibitors of the MITF molecular pathway

The present disclosure relates to novel indole and tetrahydroindole core compounds useful for the treatment of disorders associated with a defect in vesicular transport (e.g., axonal transport).

Compounds for Alzheimer's disease

The present invention provides pyrazolo[1,5-a]pyrimidine compounds which inhibit cancer-associated transporter proteins, methods of treating or preventing the onset of a cancer-associated transporter protein-mediated disease by administering such compounds, and pharmaceutical compositions comprising such compounds. In one embodiment, the invention provides pyrazolo[1,5-a]pyrimidine efflux inhibitors that are selective toward ABCG2 over ABCB1. Compounds and compositions according to the present invention may be used to treat cancer, including drug resistant (DR) and multiple drug resistant (MDR) cancers.

Selective efflux inhibitors and related pharmaceutical compositions and methods of treatment

The invention provides novel compounds useful for the treatment of neurodegenerative disorders including Alzheimer's disease and dementia. The compounds have a substituents chosen from -L-C(&#x2550;O)OH, -L-CH&#x2550;CHC(&#x2550;O)OH, -L-C(&#x2550;O)NH, -L-C(&#x2550;O)NH(Calkyl), -L-C(&#x2550;O)N(Calkyl), -L-S(&#x2550;O)(Calkyl), -L-S(&#x2550;O)NH, -L-S(&#x2550;O)N(Calkyl), -L-S(&#x2550;O)NH(Calkyl), -L-C(&#x2550;O)NHOH, -L-C(&#x2550;O)CHNH, -L-C(&#x2550;O)CHOH, -L-C(&#x2550;O)CHSH, -L-C(&#x2550;O)NHCN, -L-NHC(&#x2550;O)OR, -L-C(&#x2550;O)NHR, -L-NH(C&#x2550;O)NHR, -L-C(&#x2550;O)N(R), -L-NH(C&#x2550;O)N(R), -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.

Disclosed are 4-arylamino-quinazolines and analogs thereof that are effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

Compounds and therapeutical use thereof

Novel pyrrole derivatives are disclosed as A&#x3b2;-lowering agents for the treatment and prevention of neurodegenerative disorders characterized by the formation or accumulation of amyloid plaques comprising the A&#x3b2;peptide.

Pyrrole derivatives as therapeutic compounds

Compounds for alzheimer's disease

Growing community of inventors

Salt Lake City, UT, United States of America

Warren S Weiner